Deals25 Aug 2026, 06:41 pm
Sai Parenterals Subsidiary Renews AUD 30M Supply Agreement
AI Summary
Sai Parenterals Ltd announced that its subsidiary, Noumed Pharmaceuticals Pty Limited, has successfully renewed a long-term Over-The-Counter (OTC) Medicines Supply Agreement with a major Australian pharmacy chain. The renewed agreement spans three years and is valued at AUD 30 million (approximately ₹204 Crores), representing an increase in both value and product portfolio compared to the previous contract. The agreement is effective from August 24, 2026, and includes provisions for revision or termination with a six-month notice. This renewal underscores the subsidiary's strong relationship with its international partner and its continued growth in the Australian market.
Key Highlights
- Subsidiary Noumed Pharmaceuticals renewed a 3-year OTC medicines supply agreement.
- The renewed contract is valued at AUD 30 million (approx. ₹204 Crores).
- Agreement includes an expanded product portfolio and higher value.
- The deal is with a leading multi-billion-dollar Australian pharmacy chain.
- No promoter or group company interest in the awarding entity.
Price Impact
More from SAIPARENT